Comparison between biosimilar filgrastim vs other granulocyte‐colony stimulating factor formulations (originator filgrastim, peg‐filgrastim and lenograstim) after autologous stem cell transplantation: a retrospective survey from the Rome Transplant Network

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 2, 2015-04 ,pp. : 293-296

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation

By  

TRANSFUSION, Vol. 55, Iss. 11, 2015-11 ,pp. : 2709-2713

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cytoreduction and Stem Cell Mobilization with a Regimen of Paclitaxel, Etoposide and Cyclophosphamide Followed by Autologous Transplantation Using a Preparative Regimen of Busulfan, Etoposide and Cyclophosphamide for Patients with Advanced Lymphoma

By  

Acta Haematologica, Vol. 105, Iss. 4, 2001-08 ,pp. : 222-232

Karger

Access to resources Recommend Favorite

Filgrastim versus TBO‐filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question

By  

CLINICAL TRANSPLANTATION (ELECTRONIC), Vol. 29, Iss. 12, 2015-12 ,pp. : 1128-1132

John Wiley & Sons Inc

Access to resources Recommend Favorite

Autologous stem cell transplantation outcomes in elderly patients with B cell Non‐Hodgkin Lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 2, 2015-10 ,pp. : 197-204

John Wiley & Sons Inc

Access to resources Recommend Favorite